Abstract: The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations. The disclosure also relates to compositions comprising an insulin or insulin analog and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations.
Abstract: The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers.
Type:
Application
Filed:
October 7, 2011
Publication date:
December 19, 2013
Applicant:
UNIVERSITY OF DUNDEE
Inventors:
Andrew South, Celine Pourreyron, Stephen Watt, John Foerster
Abstract: A material combination is configured to treat or prevent inflammatory and infectious diseases caused by fastidious anaerobic or facultative anaerobic microorganisms, such as bacteria or Candida sp. The material combination includes at least one antimicrobial peptide that can be activated by a reducing substance, and at least one reducing agent.
Type:
Application
Filed:
August 19, 2011
Publication date:
December 19, 2013
Inventors:
Jan Wehkamp, Bjoern Schroeder, Eduard Stange
Abstract: The present invention relates to creatine kinase for use as a medicinal product or in the prevention or treatment of addictions or of addictive disorders associated with opiates, and to various other analytical uses or for filtration of creatine kinase.
Type:
Application
Filed:
February 3, 2012
Publication date:
December 19, 2013
Applicants:
UNIVERSITÉ DE STRABOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
Abstract: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises (a) a legumain-targeting lipid component, (b) a zwitterionic lipid component; (c) an amino-substituted lipid component; (d) a neutral lipid component; and (e) polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalenetly attached to a legumain-binding moiety.
Type:
Application
Filed:
September 2, 2011
Publication date:
December 12, 2013
Inventors:
Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
October 6, 2011
Publication date:
December 12, 2013
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
Type:
Application
Filed:
February 20, 2012
Publication date:
December 12, 2013
Applicants:
SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 2, 2011
Publication date:
November 28, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
Abstract: The invention features methods for diagnosing and treating pregnancy related complications. The invention also features methods for identifying compounds useful for treating pregnancy related complications.
Type:
Grant
Filed:
November 21, 2007
Date of Patent:
November 26, 2013
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: Described herein are materials and methods for the prophylactic treatment of a pre-malignant condition, comprising administering a SIRT1 agonist to an individual whose genotype comprises one defective BRCA1 allele and one functional BRCA1 allele.
Abstract: This disclosure relates to methods and compositions useful for treating Alzheimer's disease. In particular, the disclosure relates to pharmaceutical compositions containing an EGFR-inhibitory compound suitable for administration to treat Alzheimer's disease, as well as to related therapeutic methods. In addition, this disclosure relates to screening methods for identifying compounds useful for treating Alzheimer's disease based on the ability to inhibit the activity of EGFR.
Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
Type:
Grant
Filed:
October 19, 2009
Date of Patent:
November 12, 2013
Assignee:
Sanofi-Aventis Deutschland GmbH
Inventors:
Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
Abstract: Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided.
Abstract: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent in vivo or in vitro. The VEGFxxxb is preferably VEGF165b.
Type:
Application
Filed:
April 30, 2013
Publication date:
October 31, 2013
Inventors:
David Bates, Lucy Donaldson, Steven James Harper, Jing Hua
Abstract: The present invention is directed to a composite laminar material with high mechanical strength and methods of fabricating the material. The invention also provides a method of attaching a medical implant device to tissue.
Type:
Application
Filed:
August 30, 2011
Publication date:
October 31, 2013
Applicant:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Donald E. Ingber, Javier Gomez Fernandez
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
April 28, 2011
Publication date:
October 31, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Provided are methods for control of post-prandial glucose in diabetic subjects by administering a fast-acting insulin analog and a hyaluronidase degrading enzyme. The fast-acting insulin analog and a hyaluronidase are administered between 15 minutes before the meal and 30 minutes after commencing the meal.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
October 29, 2013
Assignee:
Halozyme, Inc.
Inventors:
Gregory I. Frost, Igor Bilinsky, Daniel Vaughn, Barry Sugarman
Abstract: A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.
Abstract: Provided is a composition for preventing or treating obesity, and more particularly, a composition for preventing or treating obesity in order to treat or improve states of obese patients requiring weight control. The composition according to the present invention has advantages in that side effects by administration of the composition are not generated, and effects of losing weight and maintaining weight are excellent without changing food intake and consumption amounts, such that the composition may be effectively used to prevent overweight and obesity related diseases.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
July 11, 2011
Publication date:
October 24, 2013
Applicants:
Pangu BioPharma Limited, a Tyr Pharma, Inc.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.
Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
Type:
Application
Filed:
March 26, 2013
Publication date:
October 17, 2013
Inventors:
Frank KAYSER, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
Abstract: Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.
Type:
Application
Filed:
February 7, 2013
Publication date:
October 17, 2013
Inventors:
Jeffry Dean Watkins, Alain Philippe Vasserot, Leslie Ann Greene, Ryan Andrew Adams, Kyle P. Chiang, Wei Zhang, Kristi Helen Piehl, Fei Hong, Alina He
Abstract: The present invention relates to the use of prokaryotic sphingosine-1-phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1-phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain.
Type:
Application
Filed:
November 30, 2011
Publication date:
October 3, 2013
Applicants:
UNIVERSITAT ZURICH, UNIVERSITAT BERN
Inventors:
Uwe Zangemeister-Wittke, Andrea Huwiler, Markus G. Grutter, Florence Bourquin
Abstract: Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure.
Type:
Application
Filed:
May 23, 2013
Publication date:
October 3, 2013
Applicant:
The Trustees of Columbia University in the City of New York
Inventors:
Benjamin Simon ELKIN, Barclay MORRISON, III, John Desmond Finan
Abstract: The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes a toxin binding domain that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.
Abstract: This invention provides chromatographic methods for the purification of a cystathionine ?-Synthase (CBS) protein, particularly truncated variants thereof and compositions and pharmaceutical compositions prepared therefrom.
Type:
Application
Filed:
March 14, 2013
Publication date:
September 26, 2013
Applicant:
THE REGENTS OF THE UNIVERSITY OF COLORADO
Inventor:
THE REGENTS OF THE UNIVERSITY OF COLORADO
Abstract: Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.
Type:
Application
Filed:
February 19, 2013
Publication date:
September 26, 2013
Inventors:
Xiaoming Li, Mysore Ramprasad, Curtis Thompson, Harold Michael Shepard, Louis Howard Bookbinder, Gregory Ian Frost
Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.
Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Type:
Application
Filed:
February 13, 2013
Publication date:
September 19, 2013
Applicants:
ATYR PHARMA, INC.
Inventors:
Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
June 1, 2011
Publication date:
September 19, 2013
Applicants:
ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: A method of treating or preventing a thrombotic disease in a subject in need thereof comprises administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein. A method of identifying an inhibitor of an apoptosis signal regulating kinase 1 (ASK1) protein useful for treating or preventing a thrombotic disease, comprising (a) contacting a candidate agent with a test sample comprising the ASK1 protein, and (b) comparing the ASK1 protein activity in the test sample with the ASK1 protein activity in a control sample that has not been contacted with the candidate agent, whereby a decrease in the ASK1 protein activity in the test sample compared with the control sample indicates that the candidate agent is an ASK1 inhibitor.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 3, 2011
Publication date:
September 12, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
Abstract: The invention provides methods of preventing or treating a condition associated with DNA damage in an animal comprising the administration of a substance that interferes with the activity of the CUL4A ubiquitin ligase. The invention also provides a substance that interferes with the activity of CUL4A, as well as compositions comprising the interfering substance and a carrier. The substance of the invention preferably enhances nucleotide excision repair activity in an animal. The invention further provides methods of identifying substances that negatively or positively modulate the expression and/or activity of CUL4A.
Abstract: Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Type:
Application
Filed:
January 29, 2013
Publication date:
September 12, 2013
Applicant:
ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Ryan Andrew Adams, Fei Hong, Ji Zhao, Eva Rebecka Stephanie Armour, Kristi Helen Piehl
Abstract: An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan.
Type:
Application
Filed:
April 8, 2013
Publication date:
September 5, 2013
Applicants:
Seikagaku Corporation, National University Corporation Nagoya University
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 4, 2011
Publication date:
September 5, 2013
Applicant:
ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
August 25, 2011
Publication date:
September 5, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 26, 2011
Publication date:
September 5, 2013
Applicants:
Pangu BioPharma Limited, aTyr Pharma Inc.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 4, 2011
Publication date:
August 29, 2013
Applicants:
PANGU BIOPHARMA LIMITED, aTyr Pharma, Inc.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
Abstract: This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 2.1.3.13)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression piasmid; transforming the host with the expression piasmid to form an expression system; expressing the GLYAT gene in the expression system; and separating the expressed GLYAT from the expression system.
Type:
Application
Filed:
August 24, 2011
Publication date:
August 29, 2013
Applicant:
North-West University
Inventors:
Lodewyk Jacobus Mienie, Alberdina Aike Van Dijk, Christoffel Petrus Stephanus Badenhorst, Rencia Van Der Sluis
Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.
Abstract: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective ?-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
July 12, 2011
Publication date:
August 29, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed.
Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
April 28, 2011
Publication date:
August 15, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Type:
Application
Filed:
May 16, 2011
Publication date:
August 15, 2013
Applicants:
PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
Inventors:
Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry Dean Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
Abstract: The invention provides methods of determining risk for stroke in a patient, as well as methods of determining a subject's need for anti-coagulation therapy. In exemplary embodiments, the method comprises measuring a level of derivatives of reactive oxygen metabolites (DROMs) in a biological sample obtained from the subject, wherein an increased level of DROMs, relative to a control level, is indicative of the subject's need for anticoagulation therapy. Further provided are methods of decreasing risk of stroke in a subject, methods of determining the efficacy of a therapeutic agent, methods of monitoring a subject's risk of stroke, and kits.
Type:
Application
Filed:
July 29, 2011
Publication date:
August 15, 2013
Applicant:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
Type:
Application
Filed:
August 5, 2011
Publication date:
August 15, 2013
Applicant:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC